Next, we knocked out COPA in 786‐O renal cancer cells (Figure S1K, Supporting Information), and found that COPA knockout could not enhance the sensitivity of 786‐O cells to sunitinib, a multitargeted TKI and standard first‐line treatment for patients with advanced renal cell carcinoma (Figure S1L‐N, Supporting Information). This evidence concerns the gene COPA and renal carcinoma.